GOVX
Price:
$2.19
Market Cap:
$20.66M
GeoVax Labs, Inc., a clinical-stage biotechnology company, develops human vaccines and immunotherapies against infectious diseases and cancers using modified vaccinia ankara virus-like particle vaccine platform. It is developing various preventive vaccines against (COVID-19), human immunodeficiency virus (HIV); Zika virus; malaria; and hemorrhagic fever viruses, such as Ebola, Sudan, Marburg, and Lassa, as well as therapeutic vaccines for HIV, chronic Hepatitis B infections, and solid tumor cancers. The company has collaboration and partnership agreements with the National Institute of Allergy and Infectious Diseases of the National Institutes of Health; Centers for Disease Control and Preve...[Read more]
Industry
Biotechnology
IPO Date
2020-09-25
Stock Exchange
NASDAQ
Ticker
GOVX
According to GeoVax Labs, Inc.’s latest financial reports and current stock price. The company's current Enterprise Value is 12.07M. This represents a change of 91.04% compared to the average of 6.32M of the last 4 quarters.
The mean historical Enterprise Value of GeoVax Labs, Inc. over the last ten years is 17.60B. The current 12.07M Enterprise Value has changed -93.14% with respect to the historical average. Over the past ten years (40 quarters), GOVX's Enterprise Value was at its highest in in the December 2018 quarter at 35.05B. The Enterprise Value was at its lowest in in the December 2022 quarter at -3610884.90.
Average
17.60B
Median
17.75B
Minimum
-3611152.90
Maximum
35.05B
Discovering the peaks and valleys of GeoVax Labs, Inc. Enterprise Value, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 6.22%
Maximum Annual Enterprise Value = 35.05B
Minimum Annual Increase = -302.53%
Minimum Annual Enterprise Value = -3611152.90
Year | Enterprise Value | Change |
---|---|---|
2023 | 7.31M | -302.53% |
2022 | -3611152.90 | -102.85% |
2021 | 126.49M | 6.22% |
2020 | 119.09M | -73.94% |
2019 | 456.93M | -98.70% |
2018 | 35.05B | 0.00% |
2017 | 35.05B | 0.00% |
2016 | 35.05B | 0.00% |
2015 | 35.05B | -0.00% |
2014 | 35.05B | 0.00% |
The current Enterprise Value of GeoVax Labs, Inc. (GOVX) is less than than its 3-year, less than than its 5-year, and less than than its 10-year historical averages
3-year avg
43.40M
5-year avg
141.24M
10-year avg
17.60B
GeoVax Labs, Inc.’s Enterprise Value is greater than eFFECTOR Therapeutics, Inc. (4.74M), greater than Virios Therapeutics, Inc. (-2813681.00), greater than Zura Bio Limited (-35434140.00), greater than Navidea Biopharmaceuticals, Inc. (-2595051.00), greater than ZyVersa Therapeutics, Inc. (2.62M), greater than Phio Pharmaceuticals Corp. (-3046990.00), greater than Sonnet BioTherapeutics Holdings, Inc. (4.34M), greater than 180 Life Sciences Corp. (3.99M), less than Cardio Diagnostics Holdings, Inc. (40.75M), less than Kiromic BioPharma, Inc. (13.21M), greater than Apexigen, Inc. (-5121682.00), greater than Altamira Therapeutics Ltd. (500.81K), greater than Avenue Therapeutics, Inc. (1.08M), greater than Quoin Pharmaceuticals, Ltd. (-439388.00), less than Blue Water Vaccines, Inc. (12.48M), greater than PaxMedica, Inc. Common Stock (437.06K), greater than Revelation Biosciences, Inc. (-3992319.00), greater than Hillstream BioPharma, Inc. (1.48M), less than Jaguar Health, Inc. (32.39M), less than Onconova Therapeutics, Inc. (33.92M), less than iBio, Inc. (15.15M), less than Ocugen, Inc. (179.18M),
Company | Enterprise Value | Market cap |
---|---|---|
4.74M | $941.00 | |
-2813681.00 | $206.50K | |
-35434140.00 | $152.79M | |
-2595051.00 | $10.01K | |
2.62M | $2.74M | |
-3046990.00 | $2.34M | |
4.34M | $4.36M | |
3.99M | $3.72M | |
40.75M | $42.01M | |
13.21M | $1.42M | |
-5121682.00 | $9.57M | |
500.81K | $1.13M | |
1.08M | $3.68M | |
-439388.00 | $2.68M | |
12.48M | $3.41M | |
437.06K | $761.54K | |
-3992319.00 | $2.55M | |
1.48M | $4.17M | |
32.39M | $11.39M | |
33.92M | $20.90M | |
15.15M | $21.96M | |
179.18M | $211.09M |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like GeoVax Labs, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like GeoVax Labs, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the Enterprise Value?
How can you use the Enterprise Value?
What is GeoVax Labs, Inc.'s Enterprise Value?
What is the highest Enterprise Value for GeoVax Labs, Inc. (GOVX)?
What is the 3-year average Enterprise Value for GeoVax Labs, Inc. (GOVX)?
What is the 5-year average Enterprise Value for GeoVax Labs, Inc. (GOVX)?
How does the current Enterprise Value for GeoVax Labs, Inc. (GOVX) compare to its historical average?